Ultra-low-dose Chest CT for HHT

Novel Ultra-low-dose Chest CT Technique to Screen for Pulmonary Arteriovenous Malformations in Pediatric Patients With Hereditary Hemorrhagic Teleangiectasia

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04874558

Enrollment

Registered

2021-05-05

Start date

2021-04-21

Completion date

2026-03-07

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Hemorrhagic Telangiectasia

Brief summary

This study aims to develop a novel ultra-low dose chest CT technology for use in Hereditary Hemorrhagic Teleangiectasia (HHT) patients and to determine the lowest possible radiation dose that is achievable without sacrificing the diagnostic quality.

Interventions

DIAGNOSTIC_TESTUltra-low dose chest CT

A novel CT technique with a new dose optimization and efficiency technology and automatic kV selection, which greatly reduces the dose of radiation exposure compared to a standard chest CT.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 17 Years

Healthy volunteers

Inclusion criteria

* Ages 1 to 17 years * Diagnosed with positive HHT causing mutations or based on Curacao criteria

Exclusion criteria

* Acute respiratory distress * Unstable cardiovascular status * Pneumothorax, hemoptysis * Pulmonary edema * Pulmonary emboli * Fractured ribs or other chest trauma * Recent bronchoscopy * Lung transplantation

Design outcomes

Primary

Measure	Time frame	Description
Ultra-low dose images PAVM detection	Baseline	Number of images detecting PAVM using the ultra-low dose images (50% or lower compared to the full dose)

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORNadir Demirel, MD

Mayo Clinic

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 25, 2026